The primary endpoint was progression-free survival (PFS; nivolumab/ipilimumab vs chemotherapy and nivolumab/ipilimumab vs nivolumab monotherapy). Findings showed the risk of disease progression or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback